Drug Profile

Eribulin mesylate - Eisai Co Ltd

Alternative Names: B-1939; B-1939 mesylate; E-7386; E-7389; ER-086526; Eribrin; Halaven; Halichondrin B Analog; NSC-707389; TECERIS

Latest Information Update: 28 May 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Eisai Co Ltd; Harvard University; Japan Agency for Medical Research and Development
Developer Academic and Community Cancer Research United; Asan Medical Center; Big Ten Cancer Research Consortium; Eisai Co Ltd; Emory University; Icahn School of Medicine at Mount Sinai; Medica Scientia Innovation Research; Merck & Co; National Cancer Center Hospital East; National Cancer Institute (USA); Pfizer; PRISM Pharma Co
Class 2 ring heterocyclic compounds; Antineoplastics; Cyclic ethers; Furans; Ketones; Macrocyclic compounds; Small molecules
Mechanism of Action Apoptosis stimulants; Cadherin modulators; Receptor protein-tyrosine kinase modulators; Transcription factor modulators; Tubulin polymerisation inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Soft tissue sarcoma
New Molecular Entity Yes

Marketed Breast cancer; Soft tissue sarcoma
Phase III Non-small cell lung cancer
Phase II Ewing's sarcoma; Glioblastoma; Haemangioendothelioma; Haemangiosarcoma
Phase I/II Colorectal cancer; Liver cancer; Malignant melanoma; Solid tumours
No development reported Ovarian cancer; Urogenital cancer
Discontinued Bladder cancer; Prostate cancer

28 May 2025 No recent reports of development identified for phase-I development in Liver-cancer(Combination therapy, Inoperable/Unresectable) in France (PO, Tablet)
28 May 2025 No recent reports of development identified for phase-I development in Liver-cancer(Combination therapy, Inoperable/Unresectable) in Japan (PO, Tablet)
28 May 2025 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy) in France (PO, Tablet)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com